ARTICLE | Company News
Genetic Therapy deal
June 20, 1994 7:00 AM UTC
GTII and Sandoz Pharma Ltd. agreed to develop and market gene therapy-based cancer products using GTII's HS-tk technology, which uses vectors for the transfer of the gene for thymidine kinase.
The agreement provides for a $6 million up-front payment and milestone payments of up to $12 million. Certain subsequent HS-tk products would carry additional up-front and milestone payments. ...